Retatrutide, an experimental weight-loss drug that could compete against blockbusters Wegovy and Zepbound, may work wonders for obese folks with liver disease, new research shows.
By Emon Reiser Lipocine said the results of its Phase 2 study evaluating LPCN 1148, a treatment to manage decompensated cirrhosis, will be presented at the.
/PRNewswire/ Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that.
NorthSea Therapeutics to Present ICONA Phase 2b Data as an Oral Late-breaker Session at the 2023 AASLD Liver Meeting finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Chronicles of trauma, crisis and buoyant memory thestatesman.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestatesman.com Daily Mail and Mail on Sunday newspapers.